Monoclonal antibodies blocking the interaction of PD-1 and PD-L1 activate an individual’s immune system to attack their cancer and have revolutionized the landscape of cancer treatment, showing clinical benefit in multiple cancers, including NSCLC. This evidence concerns the gene CD274 and cancer.